aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
Provided By GlobeNewswire
Last update: May 14, 2025
Preclinical data demonstrate ATYR0101’s unique anti-fibrotic mechanism through interaction with LTBP-1.
ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit.
Read more at globenewswire.com
